Correctsequence Therapeutics Co., Ltd

This study follows 5 people with beta-thalassemia who already received CS-101, a gene therapy that modifies their own blood stem cells. Researchers will monitor them for years to check for side effects and see if they remain free from needing blood transfusions. No new treatment …

This study checks the long-term safety and effectiveness of a gene therapy called CS-101 in 8 people with beta-thalassemia who already received the treatment. Researchers will watch for side effects and see if patients can remain transfusion-free for at least a year. No new treat…

This early-stage study tests a new gene-edited stem cell treatment (CS-101) for people with beta-thalassemia, a severe blood disorder requiring frequent transfusions. Ten participants aged 6 to 35 will receive their own genetically modified stem cells to see if it can safely redu…